Alcohol & Substance Use Disorders

🔍 Four Things You Likely Didn’t Know About Addiction

1. The “Rat Park” experiment rewrote the story of addiction. Rats given morphine water in a barren cage drink it compulsively. Give them the same water in a rich, social environment, and they largely ignore it (Alexander et al., 1981) — a finding established over four decades ago and still largely overlooked. Addiction is not just a property of the substance — it is a product of the interaction between substance, brain, and environment. The clinical parallel is striking: among our patients, those building families, pursuing meaningful work, and engaged in stimulating activity sustain the strongest recoveries — while those who are understimulated and isolated find avoiding relapse nearly impossible. Constructing a life that feels worth living to you is an essential part of keeping substance use at bay.

2. Roughly half of addiction vulnerability is genetic. Heritability estimates run 40–60% — variations in genes governing dopamine receptors, stress responses, and alcohol metabolism create very different starting lines (Verhulst et al., 2015). Some people drink socially for decades without problems; others are primed for escalation from the first exposure. What feels manageable for one person may be a neurobiological tipping point for another — other people’s experience with a substance tells you very little about your own risk.

3. Your body’s relationship with a substance can change radically — and without warning. Without a trauma history, the amygdala — the brain’s threat-detection center — typically responds to cannabis with reduced reactivity, which is why many users experience calm. But in those with trauma, the same substance can hyperactivate the amygdala, flipping the experience from relaxation to paranoia, panic, or dissociation — sometimes permanently (Neumeister et al., 2013). What felt like a reliable tool can turn on its user, and recognizing this switch is often the first step toward getting help.

4. The most effective addiction treatment is also the most underutilized. Medications for alcohol and opioid addiction reduce cravings, prevent relapse, and lower mortality — yet fewer than 10% of people with alcohol use disorder receive them (SAMHSA, 2021). They are also effective across other substance use disorders, providing what the substance provided (sleep, calm, stability) without the danger. Many benefit most during withdrawal — using medication as a bridge through intense cravings and dysregulation toward reduced use or abstinence, after which they often no longer need it.

---

📋 Overview

Substance use disorders (SUDs) are chronic, relapsing conditions characterized by compulsive substance use despite significant negative consequences. The DSM-5 conceptualizes them on a spectrum from mild to severe — replacing the older binary distinction between “abuse” and “dependence” with a more nuanced dimensional model.

SUDs affect approximately 46 million Americans annually. Alcohol use disorder alone accounts for roughly 29 million cases, contributing to an estimated 178,000 deaths per year (Esser et al., 2024).

What often goes unrecognized is that many people with substance use disorders are self-medicating — using what is essentially a poisonous substance to manage depression, anxiety, insomnia, or emotional pain that may not yet have a name, when safer and more effective treatments exist for the very condition being self-treated. This is less a story of moral failure than of inadequate information and uneven access to care.

At the neurobiological level, addiction involves progressive hijacking of the brain’s reward circuitry. The dopamine pathway that evolved to reinforce survival behaviors — eating, bonding, exploration — gets overwhelmed by substances producing dopamine surges far beyond anything natural rewards generate.

This is not truly a disease of willpower. It is a disorder of brain circuits — identifiable, measurable, and treatable.

---

🧬 Evolutionary Perspective

The circuits addiction exploits are among the most ancient in neurobiology. The mesolimbic dopamine system — situated deep in the center of the brain — evolved over hundreds of millions of years to solve a fundamental problem: how to motivate an organism to pursue survival and reproduction in an uncertain world.

In ancestral environments, this system worked elegantly. Food, water, bonding, and mating produced modest dopamine signals that reinforced approach behavior without overwhelming the system. Crucially, natural rewards involved effort, delay, and uncertainty — keeping the system in balance.

Modern addictive substances short-circuit this architecture, delivering massive dopamine surges with minimal effort — a combination the system was never designed to handle. As addiction progresses, the wanting intensifies even as the liking fades (Berridge & Robinson, 2016) — people pursue substances that may no longer bring any real pleasure because the craving has decoupled from the reward. Eventually, the substance is needed just to feel normal — a state nearly every person with a substance use disorder will recognize.

This evolutionary lens does not excuse harmful behavior. But it explains why addiction is so tenacious, why it can affect anyone regardless of intelligence or character, and why effective treatment must address the neurobiology — not just the behavior.

---

🔀 Subtypes and Presentations

Substance use disorders vary enormously depending on the substance, severity, individual neurobiology, and co-occurring conditions.

• Alcohol use disorder (AUD) — the most prevalent SUD. Presentations range from daily heavy drinking to binge patterns. Alcohol withdrawal can be medically dangerous — abrupt cessation in someone drinking heavily for years can be life-threatening, requiring supervised detoxification in a hospital or crisis setting. Chronic AUD carries significant risks including liver disease, cognitive impairment, neuropathy, and cancer.
• Opioid use disorder — involving prescription opioids, heroin, or synthetics such as fentanyl. Carries the highest acute mortality risk of any SUD due to respiratory depression. Medication-assisted treatment has the strongest evidence for reducing mortality.
• Stimulant use disorder — involving cocaine, methamphetamine, or prescription stimulants. Involves intense dopamine dysregulation and can be complicated by psychotic symptoms, cardiovascular risk, and severe lack of motivation during withdrawal as the brain readjusts to a truly normal baseline.
• Cannabis use disorder — increasingly recognized with higher-potency products and daily use. May include cognitive dulling, amotivation, and in vulnerable individuals, severe anxiety or psychotic episodes.
• Sedative/hypnotic use disorder — involving benzodiazepines, barbiturates, or newer agents. Dependence can develop with prescribed use, and withdrawal can be medically serious. The combination of benzodiazepines with opioids is particularly lethal — both suppress respiratory drive through different mechanisms, dramatically compounding overdose risk.
• Polysubstance use — simultaneous or overlapping use of multiple substances. Common, and complicates both diagnosis and treatment.

A critical clinical reality: dual diagnosis is the norm, not the exception. Approximately 50% of individuals with a lifetime SUD also meet criteria for another psychiatric condition — most commonly depression, anxiety, PTSD, bipolar disorder, or ADHD (Kessler et al., 2005). In many cases the psychiatric condition preceded the SUD; in others, the SUD worsened the psychiatric condition. Most often, the two are bidirectionally entangled, and treating one without addressing the other can be a recipe for relapse.

---

🩺 Diagnosis

Accurate diagnosis of SUDs requires a comprehensive, non-judgmental evaluation that goes well beyond confirming the presence of substance use.

• Structured clinical interview — a thorough assessment — at times developed over multiple sessions — of substance use patterns, quantity, frequency, escalation, withdrawal history, prior treatment attempts, and functional impact. Must be conducted in an atmosphere of genuine respect and confidentiality, as shame is the most common barrier to honest disclosure.
• Standardized assessment instruments — tools such as the AUDIT, DAST, and Severity of Dependence Scale can be helpful in quantifying severity and tracking progress over time.
• Comprehensive psychiatric evaluation — given the high rates of comorbidity, every SUD patient requires screening for depression, anxiety, PTSD, bipolar disorder, ADHD, and personality pathology. Failure to identify co-occurring conditions is one of the most common reasons for treatment failure.
• Medical assessment — substance use can produce or worsen a range of medical conditions. Liver function, metabolic panels, nutritional status, infectious disease screening, and cardiovascular assessment may be indicated.
• Assessment of readiness and motivation — the stages-of-change model remains useful for understanding where a patient is in relation to change and tailoring the approach accordingly.

The quality of the initial evaluation — its thoroughness, its sensitivity, and its capacity to build trust — shapes everything that follows.

---

💊 Treatment Approach

Psychotherapy

Motivational interviewing (MI) is often the starting point — a collaborative, non-confrontational approach that helps patients explore ambivalence about change, recognizing that ambivalence is normal, not a sign of insufficient motivation.

Acceptance and commitment therapy (ACT) — one of the third-wave cognitive behavioral therapies, now supported by over 1,000 randomized controlled trials across disorders — has emerged as a particularly effective approach. Rather than relying on trigger avoidance or white-knuckle resistance, ACT builds the capacity to experience cravings as passing internal events — to be observed rather than obeyed. CBT for SUDs targets learned associations between cues and substance use, building practical skills for high-risk situations. Twelve-step facilitation and mutual support groups offer community and accountability — best understood as one component of comprehensive care rather than a standalone treatment.

For patients with co-occurring PTSD, specialized integrated protocols that address trauma and substance use simultaneously have demonstrated superior outcomes to sequential treatment models.

Medication and Neuromodulation

Medication-assisted treatment (MAT) remains one of the most evidence-based yet underutilized tools in addiction medicine. For alcohol use disorder, agents that modulate the opioid reward system can reduce craving; agents that restore glutamate balance can reduce the neurobiological drive to drink; and agents producing aversive reactions support abstinence through deterrence. For opioid use disorder, long-acting agonists and partial agonists stabilize the opioid system, reduce cravings, and dramatically lower overdose death risk. Antagonists offer an alternative for patients preferring a non-agonist approach.

For stimulant use disorders, no FDA-approved medications exist yet, though several promising agents are under investigation and off-label strategies can be clinically useful.

Neuromodulation — including TMS and tDCS — is an emerging area with preliminary evidence that modulating prefrontal cortical activity can reduce craving and improve impulse control.

The right pharmacological strategy depends on the substance, severity, comorbidities, and the patient’s goals and values. Treatment is collaborative, not coercive. There is no algorithm that replaces clinical judgment shaped by deep experience with this condition.

Integrative and Lifestyle Approaches

Beyond conventional treatment, targeted interventions — including carefully selected supplements and holistic strategies — addressing neuroinflammation, gut-brain axis disruption, and nutritional deficiencies can meaningfully support recovery, particularly in the critical early months of healing. These are adjuncts, not substitutes — and the specifics are best discussed in the context of a thorough evaluation, as they are highly individual.

---

🌱 Outlook

Recovery from substance use disorders is not only possible — it is common. The majority of individuals who receive appropriate treatment achieve significant improvement (Kelly et al., 2017), and a substantial proportion achieve sustained remission. The brain’s neuroplasticity — the same property that allowed addiction to develop — also allows recovery, with measurable restoration of dopamine function, prefrontal integrity, and stress-response regulation over months to years.

Recovery is best understood not as a single event but as a process — one that may include setbacks, and in which each period of sustained recovery builds neurobiological resilience and psychological skills. Relapse is not failure but a signal that the treatment plan needs adjustment and/or the body is learning. Consider: we do not view a child falling off a bicycle as proof they will never ride. Many fall repeatedly before mastering the skill. Recovery follows a similar logic — each attempt builds the neural and psychological foundation for the next. A relapse, however disconcerting, refines the path forward rather than proving the destination is unreachable.

The single most important predictor of recovery is access to comprehensive, evidence-based, individualized treatment — delivered without judgment, with appreciation of the complexity of the situation, and sustained over time.

---

🏥 How to Get Better

At our psychiatry practice, we have extensive experience in treating alcohol and substance use disorders and bring a thoughtful, evidence-based approach to managing them with medications – when needed – and psychotherapy and — when appropriate and desired by the patient — with other modalities including supplements, neuromodulation, and holistic practices.

For substance use disorders, we regularly collaborate with interventionists and high-intensity facilities for medically supervised detoxification or residential rehabilitation when needed. That said, in many cases, an intensive outpatient course of treatment with our practice has been sufficient to significantly reduce the duration of — or eliminate the need for — residential programs that can cost $40,000–$60,000 per month, often out of pocket.

Ready to get started? Schedule an intake appointment — a thorough evaluation where we clarify your diagnosis, map out your treatment plan, and get everything moving: medication orders, therapy, supplements, and nutrition. Your care begins the same day, not weeks later.

Schedule Your Intake

We offer statewide telehealth services in California and Florida, with in-person appointments available in Los Angeles and Miami. We also regularly assist international patients due to our fluency in Portuguese, Spanish, and Farsi.

---

📚 References

1. American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). American Psychiatric Publishing.
2. Volkow, N. D., Koob, G. F., & McLellan, A. T. (2016). Neurobiologic advances from the brain disease model of addiction. New England Journal of Medicine, 374(4), 363–371.
3. Alexander, B. K., Beyerstein, B. L., Hadaway, P. F., & Coambs, R. B. (1981). Effect of early and later colony housing on oral ingestion of morphine in rats. Pharmacology Biochemistry and Behavior, 15(4), 571–576.
4. Berridge, K. C., & Robinson, T. E. (2016). Liking, wanting, and the incentive-sensitization theory of addiction. American Psychologist, 71(8), 670–679.
5. Verhulst, B., Neale, M. C., & Kendler, K. S. (2015). The heritability of alcohol use disorders: a meta-analysis of twin and adoption studies. Psychological Medicine, 45(5), 1061–1072.
6. Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62(6), 617–627.
7. Moss, H. B., Chen, C. M., & Yi, H. (2007). Subtypes of alcohol dependence in a nationally representative sample. Drug and Alcohol Dependence, 91(2-3), 149–158.
8. Koob, G. F., & Volkow, N. D. (2016). Neurobiology of addiction: a neurocircuitry analysis. The Lancet Psychiatry, 3(8), 760–773.
9. Substance Abuse and Mental Health Services Administration. (2021). Key Substance Use and Mental Health Indicators in the United States: Results from the 2020 National Survey on Drug Use and Health. SAMHSA.
10. Kranzler, H. R., & Soyka, M. (2018). Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA, 320(8), 815–824.
11. Miller, W. R., & Rollnick, S. (2013). Motivational Interviewing: Helping People Change (3rd ed.). Guilford Press.
12. Kosten, T. R., & George, T. P. (2002). The neurobiology of opioid dependence: implications for treatment. Science & Practice Perspectives, 1(1), 13–20.
13. Esser, M. B., Sherk, A., Liu, Y., et al. (2024). Deaths and years of potential life lost from excessive alcohol use — United States, 2016–2021. MMWR Morbidity and Mortality Weekly Report, 73(8), 154–161.
14. Neumeister, A., Normandin, M. D., Pietrzak, R. H., et al. (2013). Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Molecular Psychiatry, 18(9), 1034–1040.
15. Kelly, J. F., Bergman, B., Hoeppner, B. B., Vilsaint, C., & White, W. L. (2017). Prevalence and pathways of recovery from drug and alcohol problems in the United States population: Implications for practice, research, and policy. Drug and Alcohol Dependence, 181, 162–169.